Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults
about
Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457TVaccines against human diarrheal pathogens: current status and perspectivesGut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans.Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteersCharacterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice.Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamicsLive bacterial vaccines--a review and identification of potential hazards.Prevention and self-treatment of traveler's diarrhea.Plant-derived vaccines against diarrhoeal diseases.Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia.Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.Live-attenuated Shigella vaccines.Use of attenuated bacteria as delivery vectors for DNA vaccines.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Type III secretion systems and disease.Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.Clinical Trial of an Oral Live Shigella sonnei Vaccine Candidate, WRSS1, in Thai Adults.Progress and pitfalls in Shigella vaccine research.Shigella Vaccine Development: Finding the Path of Least Resistance.An update on vaccines against Shigella.Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta)Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae.Reaching a consensus on management practices and vaccine development targets for mitigation of infectious diarrhoea among deployed US military forces.Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal DiseasesA clinically parameterized mathematical model of Shigella immunity to inform vaccine design.Live non-invasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model.T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans.
P2860
Q22065494-BF3FE1AE-1099-42B3-8DCD-A7E3B45D1DD1Q33578045-BC397750-605A-4FFD-86A1-923706064BF0Q34068059-F73A5977-F9FF-4828-A021-AB7054A79454Q34194587-DFFFB9CF-CE02-48E0-AA01-D966B9B793C5Q34394744-4299E54B-927B-4BA8-9A28-3F9C6C4BC56EQ34429033-C797F758-54E6-44F9-BEE2-7AB090555B59Q34669980-0B481CD6-F4AA-4BD1-934C-9E3584B8A2C7Q34974711-5C5C0D8A-DBAB-405D-B523-337E17CCCA30Q34974972-3E8CD257-6464-46B1-A9CD-B6DE8A26D547Q35779390-407E2334-4ACC-4C8A-AE1C-1A45A6E91802Q35804868-51BA65A5-9819-48A6-A705-A2694B50AF25Q35887055-BB4A80ED-0D78-4E67-B102-F26C842FBEE2Q36284542-8B592960-FEED-4855-85CF-42BF3BF9E9B7Q36689023-58A5B8A1-0539-43D7-8558-FF72C54C3771Q36728805-F589DB67-1881-4FAA-ACD1-F0DB13626E0CQ36844719-B3173858-0C9E-478F-85D1-770226D21E24Q36969851-C8E96601-4A9E-46ED-AEA5-CDA04F1E3BD0Q37032264-12BF4BE8-E5CF-4EC5-BEB3-E097860FFB14Q37067290-A670F899-08FA-485D-B65F-226D1238E86FQ37105553-C582D857-BEDC-4EE8-90CF-E911E2F4532DQ37477191-797EEBBA-F2B4-4CDD-A3A1-2596872197A7Q37668395-A5675973-90B9-49C7-A53A-CC6B30F57941Q38294092-1C22FC9A-D8FF-4D12-8922-36B20902DCD6Q38952300-D9881DA0-55D3-4DA5-BE90-7CD83EFDDF89Q39397885-B8EA996D-EFD1-4F9C-905A-ADC89C21664FQ39655324-99B4F793-0653-411B-819F-65C350692A53Q40469794-406A393F-C7FE-4A33-8F56-FBB5E12DC69AQ42554197-E4DF32AC-17C1-41E2-9C77-67B2BD74B579Q47205506-E484EA24-4A1E-492C-B6BB-E7C0DD8A7B07Q50039350-3A8F0D70-F19D-41E2-9198-60B9063AAF8EQ52657631-FCB97D5F-CF96-4349-9188-ABA9330911F6
P2860
Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@ast
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@en
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@nl
type
label
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@ast
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@en
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@nl
prefLabel
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@ast
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@en
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@nl
P2093
P2860
P50
P1476
Phase I evaluation of delta vi ...... strain WRSS1 in healthy adults
@en
P2093
Antoinette Hartman
David E Katz
David N Taylor
Genevieve A Losonsky
James D Campbell
Malabi Venkatesan
Marcelo B Sztein
Steven S Wasserman
Thomas L Hale
William D Picking
P2860
P304
P356
10.1128/IAI.70.4.2016-2021.2002
P407
P577
2002-04-01T00:00:00Z